周剂量白蛋白结合型紫杉醇联合SOX方案一线治疗晚期胃癌的临床观察

Effects of weekly dose abraxane combined with SOX in the first-line treatment of patients with advanced gastric cancer

目的:对周剂量白蛋白结合型紫杉醇(PTX)+SOX方案用于晚期胃癌(GC)患者一线治疗的临床效果与不良反应(AR)展开观察与评价。方法:选择2017年1月~2019年12月就诊于扬州市江都区人民医院的38例晚期转移性GC患者,均予以周剂量白蛋白结合型PTX联合SOX方案治疗,回顾性分析其治疗效果和安全性。结果:38例患者皆可评估疗效。完全缓解(CR)0例,部分缓解(PR)16例,疾病稳定(SD)15例,疾病进展(PD)7例,中位无进展生存期(PFS)、中位总生存期(OS)分别为7个月、15个月。患者血清肿瘤标志物化疗完成后较化疗前下降(P<0.05),患者免疫功能化疗完成后较化疗前改善。血液毒性方面主要为中性粒细胞减少及血小板减少,非血液毒性主要为乏力、便秘、恶心呕吐、神经毒性、脱发,大部分患者均能耐受上述不良反应。结论:周剂量白蛋白结合型(PTX)+SOX化疗方案用于晚期GC一线治疗,可获得确切疗效,具有良好的安全性,具备深入分析价值。

Objective To evaluate the efficacy and adverse effects of weekly dose abraxane combined with SOX in the first-line treatment of patients with advanced gastric cancer.Method From January 2017 to December 2019,38 patients with advanced metastatic gastric cancer in Yangzhou Jiangdu people's hospital were treated with weekly dose of abraxane combined with SOX,and the therapeutic effect and safety were retrospectively analyzed.Results 38 patients can evaluate the curative effect.There were no complete remission(CR),16 partial remission(PR),15 stable disease(SD)and 7 progressive disease(PD).The median PFS was 7 months and the median OS was 15 months.The tumor index of patients after chemotherapy decreased compared with that before chemotherapy(P<0.05),and the immune function of patients after chemotherapy improved compared with that before chemotherapy.In terms of hematotoxicity,neutropenia and thrombocytopenia were the main toxicities,while non hematotoxicity included fatigue,constipation,nausea and vomiting,neurotoxicity and alopecia.Conclusion Weekly dose of abraxane combined with SOX is effective and safe in the first-line treatment of advanced gastric cancer,which is worthy of further study.